Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288787 | 0.91 | PTGER4 (0.46) | SCDTP53ALDH1A1MAPTPTGER4 | |
| SCHEMBL6288965 | 0.85 | SCD (0.40) | SCDTP53ALDH1A1KDM4ELMNA | |
| SCHEMBL6289016 | 0.84 | SCD (0.43) | SCDALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6289334 | 0.80 | ALDH1A1 (0.43) | SCDCNR2TP53ALDH1A1KDM4E | |
| SCHEMBL6292196 | 0.80 | SCD (0.54) | SCDCNR2TP53ALDH1A1LMNA | |
| SCHEMBL6289349 | 0.76 | SCD (0.38) | SCDALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6696978 | 0.76 | PTGER4 (0.46) | SCDTP53ALDH1A1LMNAHPGD | |
| SCHEMBL6696562 | 0.76 | PTGER4 (0.42) | SCDPTGER4 | |
| SCHEMBL6288755 | 0.72 | TP53 (0.45) | TP53ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6701922 | 0.72 | SCD (0.36) | SCDTP53KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | SCD 2142/4885CNR2 3386/4885TP53 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.